Background: Salvianolic acid A (SAA) is a polyphenolic acid extracted from Salvia miltiorrhiza Bunge. It showed protective effect against diabetic complications after oral administration with a low bioavailability of 1.42%. Attempts have been made to develop it into a new medication. Intracorporal process of SAA is indistinct and no report regarding the excretion is available. Our preliminary experiment revealed that previous reported methods were unsuitable for the excretion study due to the serious matrix effect.
Methods: To better clarify its pharmacokinetics and avoid the interference of complex endogenous substances, a sensitive UPLC-MS/MS method with a better resolution was developed for the excretion study of SAA for the first time. The analytes were separated by reversed-phase chromatography with acetonitrile-water (containing 0.1% formic acid) gradient elution. The mass spectrometer was operated in the negative ESI mode and multiple reaction monitoring mode.
Results: This method was linear over the concentration range of 2.5-100, 5-100 and 5-100 ng/mL in urine, feces and bile, respectively. The accuracy, precision, stability, recovery and matrix effect were satisfactory in all matrices examined. The validated method was successfully applied to an excretion study in rats. After oral administration of 20 mg/kg, the average accumulated excretion amount of SAA in urine, feces and bile were 99.80, 32046.30 and 161.03 ng, respectively.
Conclusion: A quick but low elimination was observed. The date is useful for the clinical trial design of SAA.
Keywords: Salvianolic acid A, UPLC-MS/MS, rat, excretion, sensitivity, resolution.
Modelling of Aldose Reductase Inhibitory Activity of Pyrrol-1-yl-acetic Acid Derivatives by Means of Multivariate Statistics
Medicinal Chemistry Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-( 1-12) Axis in the Pathogenesis of Diabetic Retinopathy
Current Medicinal Chemistry ACE2 and Diabetic Complications
Current Pharmaceutical Design Ambulatory Blood Pressure Monitoring in Type 2 Diabetes Mellitus: A Cross-sectional Study
Current Hypertension Reviews Predictive Factors of follow-up Non-attendance and Mortality Among Adults with Type 2 Diabetes Mellitus- an Analysis of the Malaysian Diabetes Registry 2009
Current Diabetes Reviews Angiotensin and Bradykinin: Targets for the Treatment of Vascular and Neuro-Glial Pathology in Diabetic Retinopathy
Current Pharmaceutical Design Neuroprotection by Resveratrol in Diabetic Neuropathy: Concepts & Mechanisms
Current Medicinal Chemistry Non-Insulin Dependent Diabetes Mellitus: Present Therapies and New Drug Targets&#
Mini-Reviews in Medicinal Chemistry Role of Methylglyoxal in Diabetic Cardiovascular and Kidney Diseases: Insights from Basic Science for Application into Clinical Practice
Current Pharmaceutical Design Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Current Pharmaceutical Design Recent Studies on Neural Tube Defects in Embryos of Diabetic Pregnancy: An Overview
Current Medicinal Chemistry Recent Studies of Aldose Reductase Enzyme Inhibition for Diabetic Complications
Current Medicinal Chemistry Discovery of Potential Sorbitol Dehydrogenase Inhibitors from Virtual Screening
Medicinal Chemistry Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry Role of Nitrosative Stress and Peroxynitrite in the Pathogenesis of Diabetic Complications. Emerging New Therapeutical Strategies
Current Medicinal Chemistry Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology Tapping into Mitochondria to Find Novel Targets for Diabetes Complications
Current Drug Targets Type 2 Diabetes and Risk for Functional Decline and Disability in Older Persons
Current Diabetes Reviews Compounds that Combine Aldose Reductase Inhibitory Activity and Ability to Prevent the Glycation (Glucation and/or Fructation) of Proteins as Putative Pharmacotherapeutic Agents
Drug Design Reviews - Online (Discontinued) The GSTM1 and GSTT1 Null Genotypes Increase the Risk for Type 2 Diabetes Mellitus and the Subsequent Development of Diabetic Complications: A Meta-analysis
Current Diabetes Reviews